EGFR and non-small cell lung carcinoma: In particular, EGFR mutation is common in never-smoker Asian female [25,26] and previous study demonstrated that the effect of EGFR-tyrosine kinase inhibitor therapy of non-small-cell lung cancer was better response in female than male [27].